Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 5Phase 3 4Phase 1/2 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 2Genitourinary 2Tumor-Agnostic 1Thoracic 1Head & Neck 1

Conditions

Carcinoma, Renal Cell 2Prostatic Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × sitravatinib × Clear all
NCT03666143 2024-11-04

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

BeiGene

Phase 1 Completed
216 enrolled 20 charts
Other solid neoplasm

Advanced Solid Tumors

NCT04472650 2024-10-26

Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults

BeiGene

Phase 1 Completed
26 enrolled 14 charts
Tumor-Agnostic

Neoplasms

NCT04518046 2024-06-05

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Mirati Therapeutics Inc.

Phase 1 Completed
22 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04887194 2024-05-08

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Mirati Therapeutics Inc.

Phase 1 Completed
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT02219711 2023-03-06

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Mirati Therapeutics Inc.

Phase 1 Completed
193 enrolled
GenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡